Literature DB >> 29634943

T Cell Dysfunction in Cancer.

Daniela S Thommen1, Ton N Schumacher2.   

Abstract

Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence from studies in murine and human cancer suggest that intratumoral T cells display a broad spectrum of (dys-)functional states, shaped by the multifaceted suppressive signals that occur within the tumor microenvironment. Here we discuss the current understanding of T cell dysfunction in cancer, the value of novel technologies to dissect such dysfunction at the single cell level, and how our emerging understanding of T cell dysfunction may be utilized to develop personalized strategies to restore antitumor immunity.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PD-1; T cell exhaustion; cancer; cancer immunotherapy; single cell technologies; tumor microenvironment

Mesh:

Year:  2018        PMID: 29634943     DOI: 10.1016/j.ccell.2018.03.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  290 in total

1.  Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.

Authors:  Jonathan J Pinney; Fátima Rivera-Escalera; Charles C Chu; Hannah E Whitehead; Karl R VanDerMeid; Ashley M Nelson; Michelle C Barbeau; Clive S Zent; Michael R Elliott
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

Review 2.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 3.  CAR T cells and checkpoint inhibition for the treatment of glioblastoma.

Authors:  Steven H Shen; Karolina Woroniecka; Andrew B Barbour; Peter E Fecci; Luis Sanchez-Perez; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2020-02-17       Impact factor: 4.388

Review 4.  Humanized mouse model: a review on preclinical applications for cancer immunotherapy.

Authors:  Ling Yin; Xue-Jing Wang; De-Xi Chen; Xiao-Ni Liu; Xiao-Jun Wang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

5.  PHA eludes macrophage suppression to activate CD8+ T cells.

Authors:  Yelizavet D Lomakova; Jennifer Londregan; Jeffrey Maslanka; Naomi Goldman; John Somerville; James E Riggs
Journal:  Immunobiology       Date:  2018-11-03       Impact factor: 3.144

6.  CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment.

Authors:  Takayoshi Yamauchi; Toshifumi Hoki; Takaaki Oba; Hidehito Saito; Kristopher Attwood; Michael S Sabel; Alfred E Chang; Kunle Odunsi; Fumito Ito
Journal:  JCI Insight       Date:  2020-04-23

7.  Single-Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment.

Authors:  Anuja Sathe; Susan M Grimes; Billy T Lau; Jiamin Chen; Carlos Suarez; Robert J Huang; George Poultsides; Hanlee P Ji
Journal:  Clin Cancer Res       Date:  2020-02-14       Impact factor: 12.531

8.  Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Authors:  Heinz Läubli; Stefan Dirnhofer; Alfred Zippelius
Journal:  Virchows Arch       Date:  2018-08-25       Impact factor: 4.064

9.  Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 + T Cells.

Authors:  Benjamin J Meckiff; Ciro Ramírez-Suástegui; Vicente Fajardo; Serena J Chee; Anthony Kusnadi; Hayley Simon; Alba Grifoni; Emanuela Pelosi; Daniela Weiskopf; Alessandro Sette; Ferhat Ay; Grégory Seumois; Christian H Ottensmeier; Pandurangan Vijayanand
Journal:  SSRN       Date:  2020-07-07

10.  Notch signaling defects in NK cells in patients with cancer.

Authors:  Gulnur K Zakiryanova; Elena Kustova; Nataliya T Urazalieva; Emile T Baimukhametov; Valeriy A Makarov; Gulmariya M Turaly; Galina V Shurin; Zarema M Biyasheva; Narymzhan N Nakisbekov; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2020-10-21       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.